

In an update of the BArT study, direct-acting antivirals led to durable responses in HCV-associated indolent B-cell lymphomas, with 6-year progression-free survival of 66% and no relapses after a complete response.
Gastroenterology
|11th Mar, 2026
|The New England Journal of Medicine
Gastroenterology
|11th Mar, 2026
|The New England Journal of Medicine
Gastroenterology
|11th Mar, 2026
|The New England Journal of Medicine
Gastroenterology
|11th Mar, 2026
|The New England Journal of Medicine
Gastroenterology
|11th Mar, 2026
|The New England Journal of Medicine
Gastroenterology
|11th Mar, 2026
|The New England Journal of Medicine
Gastroenterology
|11th Mar, 2026
|The New England Journal of Medicine